Phase 3 Trial Testing Biosimilar to Rituxan, JHL1101, in DLBCL Patients Begins
News
Patient dosing has begun in a Phase 3 trial comparing JHL Biotech‘s proposed biosimilar of rituximab JHL1101 to the original medicine, Rituxan (rituximab), in diffuse large B-cell lymphoma (DLBCL), the company announced. The ... Read more